Try our Advanced Search for more refined results
USA v. Babich et al
Case Number:
1:16-cr-10343
Court:
Nature of Suit:
Judge:
Firms
- Clark Hill
- Donnelly Conroy
- Fick & Marx
- Fitch Law Partners
- Hogan Lovells
- King & Spalding
- Kobre & Kim
- Miner Siddall
- Morgan Lewis
- Nixon Peabody
- Ropes & Gray
- Weil Gotshal
- White & Case
- Wilkinson Stekloff
Companies
Sectors & Industries:
-
March 01, 2019
Insys Was 'Up Front' With MDs About Bribes, Ex-VP Testifies
Insys Therapeutics Inc. left nothing to chance when bribing doctors, making it clear they were expected to write as many prescriptions as possible for Insys' opioid spray in exchange for lucrative speaking gigs, the company's former sales VP testified Friday in Boston federal court.
-
February 25, 2019
'The Spiel' Helped Insys Get Opioid Spray Paid For, Exec Says
Insys Therapeutics Inc. employees used "the spiel" to sidestep insurance companies' questions so they would cover an expensive opioid spray for patients who did not require the powerful medication, a former manager testified Monday in a Boston federal courtroom during a conspiracy trial for five former executives.
-
February 22, 2019
Insys Rode 'The Gray Line' To Mislead Insurers, Exec Says
Insys Therapeutics Inc. routinely lied to insurance companies, training employees to "ride the gray line" between truth and fiction in order to get expensive fentanyl prescriptions covered, a former manager testified Friday in Boston federal court during a trial for company brass accused of bribing doctors to prescribe the drug.
-
February 15, 2019
'We're All Going To Jail,' Ex-Insys CEO Says He Heard At Work
The former CEO of Insys Therapeutics Inc. on Friday described a messy internal battle after the government started investigating a speaker program allegedly used to bribe doctors to prescribe opioids, saying before jurors in Massachusetts federal court that he once heard another executive shout "we are all going to jail."
-
February 14, 2019
Ex-Insys CEO Says Founder Called Him Company's 'Fall Guy'
Insys Therapeutics Inc. founder John Kapoor told former CEO Michael Babich that Babich would be the "fall guy" for the company as it began to face scrutiny, Babich testified to a Boston federal jury Thursday in the racketeering trial of Kapoor and four other former executives.
-
February 12, 2019
Ex-Insys CEO Says Founder Demanded Aggressive Marketing
Former Insys Therapeutics CEO Michael Babich told a Boston federal jury Tuesday that founder John Kapoor was the company's primary shot-caller in the development of an aggressive marketing strategy that ultimately led to what prosecutors say was a scheme to bribe doctors.
-
February 11, 2019
Insys Paid For Painkiller Prescriptions, Nurse Tells Jury
A former Connecticut nurse practitioner testified in Boston federal court Monday that greed led her to prescribe a fentanyl-based painkiller to patients who didn't need it, saying representatives from Insys Therapeutics told her she had to prescribe its drug if she wanted money for attending sham speaker events.
-
February 01, 2019
Ex-Insys Exec Testifies On Blowing Up At Founder
The former vice president of marketing at Insys Therapeutics shouted at founder John Kapoor during a 2012 meeting in an attempt to stop the company from turning its physician speaker program into what amounted to a scheme to bribe doctors, he told a Boston federal jury Friday.
-
January 28, 2019
Ex-Insys Execs Driven By Greed To Bribe Doctors, Jury Hears
Greed drove Insys Therapeutics Inc.'s wealthy founder and four company executives to spend millions bribing doctors to prescribe an expensive opioid spray, a federal prosecutor said as a closely watched trial began Monday in Boston, with the executives claiming all they did was legally market their drug.
-
January 24, 2019
Insys Trial A Salvo In 'Militaristic' Gov't Attack On Opioids
A bribery trial starting Monday for a group of former Insys Therapeutics Inc. executives is one layer in a "militaristic" government attack on the opioid crisis in Massachusetts, one in which experts say everyone from billion-dollar companies to individual prescribers are under the microscope.